Your about to leave the site and are being redirected to another site. Would you like to leave this site?

Image-1

NOW

APPROVED

Image-1

The FIRST AND ONLY FDA-approved anti-PD-L1 immunotherapy for adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC)1

Register here for a webcast introducing BAVENCIO.

indication

BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Visit CoverOne.com to learn about patient access and reimbursement support for BAVENCIO—or call 844-8COVER1
(844-826-8371).